Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.